Crossmark

The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies

Crossref DOI link: https://doi.org/10.1038/s41419-024-06837-w

Published Online: 2024-06-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yu, Puguang

Zhu, Chunming

You, Xiangyun

Gu, Wen

Wang, Xia

Wang, Yuan

Bu, Renge

Wang, Kefeng https://orcid.org/0000-0003-0014-9182
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82072835)
License Information

Text and Data Mining valid from 2024-06-19

Version of Record valid from 2024-06-19
More Information

Article History

Received: 20 January 2024

Revised: 8 June 2024

Accepted: 13 June 2024

First Online: 19 June 2024

Competing interests

: The authors declare no competing interests.

: Not applicable.

: Not applicable.

Document is current

Any future updates will be listed below